Fig. 1From: Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective studyScores on the numeric rating scale (NRS) were significantly reduced after 8 weeks of treatment with mirogabalin. Data are expressed as the mean ± standard deviation. *p < 0.05Back to article page